Potential cytokine biomarkers in autism spectrum disorders

Biomarkers in Medicine

Volumn 8, Issue 9, 2014, Pages 1171-1181

  Rose, Destanie ^a,b   Ashwood, Paul ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism spectrum disorders; Biomarkers; Chemokines; Cytokines; Immune system; Maternal immune system

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AMNION FLUID; AUTISM; CEREBROSPINAL FLUID; CHILD BEHAVIOR; DISEASE ASSOCIATION; DISEASE SEVERITY; FETUS MONITORING; GESTATIONAL AGE; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NERVOUS SYSTEM INFLAMMATION; NEWBORN PERIOD; PRENATAL PERIOD; PROTEIN BLOOD LEVEL; REVIEW; T LYMPHOCYTE; BLOOD; IMMUNOLOGY;

BIOLOGICAL MARKERS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CYTOKINES; HUMANS;

EID: 84911462588     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/BMM.14.39     Document Type: Review

References (53)

1. Baio J, Autism, Developmental Disabilities Monitoring Network Surveillance Year Principal I, Centers for Disease C, Prevention: Prevalence of Autism Spectrum Disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. Morbid. Mortal. Wkly Rep. Surveill. Summ. 61(3), 1-19 (2012).
2. Ruggeri B, Sarkans U, Schumann G, Persico AM. Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology 231(6), 1201-1216 (2013.
3. Cohen MC, Cohen S. Cytokine function: a study in biologic diversity. Am. J. Clin. Pathol. 105(5), 589-598 (1996).
4. Deverman BE, Patterson PH. Cytokines and CNS development. Neuron 64(1), 61-78 (2009).
5. Derecki NC, Cardani AN, Yang CH et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207(5), 1067-1080 (2010).
6. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat. Rev. Neurosci. 8(3), 221-232 (2007).
7. Dinarello CA. Historical insights into cytokines. Eur. J. Immun. 37(Suppl. 1), S34-S45 (2007).
8. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav. Immun. 26(3), 383-392 (2012).
9. Mannion A, Leader G, Healy O. An investigation of comorbid psychological disorders, sleep problems, gastrointestinal symptoms and epilepsy in children and adolescents with Autism Spectrum Disorder. Res. Autism Spectrum Dis. 7(1), 35-42 (2013).
10. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57(1), 67-81 (2005).
11. Li X, Chauhan A, Sheikh AM et al. Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 207(1-2), 111-116 (2009).
12. Morgan JT, Chana G, Pardo CA et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psych. 68(4), 368-376 (2010).
13. Garbett K, Ebert PJ, Mitchell A et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 30(3), 303-311 (2008).
14. Stubbs EG, Crawford ML. Depressed lymphocyte responsiveness in autistic children. J. Autism Child. Schizophr. 7(1), 49-55 (1977).
15. Abdallah MW, Larsen N, Mortensen EL et al. Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank. J. Neuroimmunol. 252(1-2), 75-82 (2012).
16. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van De Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav. Immun. 25(1), 40-45 (2011).
17. Manzardo AM, Henkhaus R, Dhillon S, Butler MG. Plasma cytokine levels in children with autistic disorder and unrelated siblings. Int. J. Develop. Neurosci. 30(2), 121-127 (2012).
18. Napolioni V, Ober-Reynolds B, Szelinger S et al. Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder. J. Neuroinflammation 10, 38 (2013).
19. Suzuki K, Matsuzaki H, Iwata K et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS ONE 6(5), e20470 (2011).
20. Tobiasova Z, Van Der Lingen KH, Scahill L et al. Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. J. Child Adol. Psychopharmacol. 21(6), 555-564 (2011).
21. Al-Ayadhi LY, Mostafa GA. Elevated serum levels ofinterleukin-17A in children with autism.. J. Neuroinflammation 9, 158 (2012).
22. Ashwood P, Enstrom A, Krakowiak P et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J. Neuroimmunol. 204(1-2), 149-153 (2008).
23. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 45(1), 1-6 (2002).
24. El-Ansary AK, Ben Bacha AG, Al-Ayadhi LY. Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia. J. Neuroinflamm. 8, 142 (2011).
25. Emanuele E, Orsi P, Boso M et al. Low-grade endotoxemia in patients with severe autism. Neurosci. Lett. 471(3), 162-165 (2010).
26. Okada K, Hashimoto K, Iwata Y et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(1), 187-190 (2007).
27. Ricci S, Businaro R, Ippoliti F et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox. Res. 24(4), 491-501 (2013).
28. Singh VK. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J. Neuroimmunol. 66(1-2), 143-145 (1996).
29. Singh VK, Warren RP, Odell JD, Cole P, et al. Changes of soluble interleukin-2, interleukin-2 receptor, T8antigen, and interleukin-1 in the serum of autistic children. Erratum in: Clin. Immunol. Immunopathol.63 (3), 292 (1992). Clin. Immunol. Immunopathol. 61(3), 448-455 (1991).
30. Sweeten TL, Posey DJ, Shankar S, Mcdougle CJ. High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol. Psych. 55(4), 434-437 (2004).
31. Zimmerman AW, Jyonouchi H, Comi AM et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr. Neurol. 33(3), 195-201 (2005).
32. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324(6092), 73-76 (1986).
33. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Ann. Rev. Immunol. 15, 797-819 (1997).
34. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 54, 1-78 (1993).
35. Zaretsky MV, Alexander JM, Byrd W, Bawdon RE. Transfer of inflammatory cytokines across the placenta. Obstet. Gynecol. 103(3), 546-550 (2004).
36. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2(4), 241-248 (1995).
37. Gottesman, Ii, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psych. 160(4), 636-645 (2003).
38. Grigorenko EL, Han SS, Yrigollen CM et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 122(2), e438-e445 (2008).
39. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van De Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J. Neuroimmunol. 232(1-2), 196-199 (2011).
40. Bauman ML. Medical comorbidities in autism: challenges to diagnosis and treatment. Neurotherapeutics 7(3), 320-327 (2010).
41. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann. Rev. Immunol. 18, 217-242 (2000).
42. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children. J. Neuroinflammation 10, 72 (2013).
43. Abdallah MW, Larsen N, Grove J et al. Amniotic fluid inflammatory cytokines: potential markers of immunologic dysfunction in autism spectrum disorders. World J. Biol. Psychiatry 14(7), 528-538 (2013).
44. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129(4), 263-276 (2002).
45. Shattuck PT, Seltzer MM, Greenberg JS et al. Change in autism symptoms and maladaptive behaviors in adolescents and adults with an autism spectrum disorder. J. Autism Develop. Dis. 37(9), 1735-1747 (2007).
46. Goines PE, Croen LA, Braunschweig D et al. Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: a case-control study. Mol. Autism 2, 13 (2011).
47. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan. Med. Bull. 45(3), 320-323 (1998).
48. Abdallah MW, Larsen N, Grove J et al. Neonatal chemokine levels and risk of autism spectrum disorders: findings from a Danish historic birth cohort follow-up study. Cytokine 61(2), 370-376 (2013).
49. Abdallah MW, Larsen N, Grove J et al. Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort. Brain Behav. Immun. 26(1), 170-176 (2012).
50. Grether JK, Anderson MC, Croen LA, Smith D, Windham GC. Risk of autism and increasing maternal and paternal age in a large north American population. Am. J. Epidemiol. 170(9), 1118-1126 (2009).
51. Heuer L, Ashwood P, Schauer J et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res. 1(5), 275-283 (2008).
52. Iwata Y, Tsuchiya KJ, Mikawa S et al. Serum levels of P-selectin in men with high-functioning autism. Br. J. Psych. 193(4), 338-339 (2008).
53. Kajizuka M, Miyachi T, Matsuzaki H et al. Serum levels of platelet-derived growth factor BB homodimers are increased in male children with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(1), 154-158 (2010).